All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
ASH 2022: Top abstracts in MM and other plasma cell dyscrasias
Bookmark this article
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members provided their recommendations for the top presented abstracts in multiple myeloma and other plasma cell dyscrasias.
Additional publications about the latest data presented at ASH 2022 can be found here.
Newly diagnosed multiple myeloma
|
569 |
Salomon Manier |
|
|
570 |
Charlotte Pawlyn |
|
|
643 |
Tracking the Earliest Genomic Events in Multiple Myeloma Life-History |
Anthony Cirrincione |
|
644 |
Martin F Kaiser |
|
|
754 |
John R Jones |
|
|
762 |
Kwee Yong |
|
|
865 |
Laura Notarfranchi |
|
|
870 |
Ben A Derman |
|
|
969 |
Sunil Lakhwani |
Relapsed and/or refractory multiple myeloma
Other plasma cell dyscrasias
|
107 |
Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort |
Elias Eythorsson |
|
108 |
Romanos Sklavenitis-Pistofidis |
|
|
118 |
Maria-Victoria Mateos |
|
|
757 |
Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial |
Shaji K Kumar |
|
760 |
Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis in the Phase 3 VITAL Study Consistent after Adjustment for Key Baseline Variables |
Morie A Gertz |
|
761 |
Efstathios Kastritis |
|
|
967 |
Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study |
Robert Palmason |
More about...
Your opinion matters
59 votes - 52 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox